KRAS G12A
Clinical trials for KRAS G12A explained in plain language.
Never miss a new study
Get alerted when new KRAS G12A trials appear
Sign up with your email to follow new studies for KRAS G12A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-stage study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, or related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. …
Matched conditions: KRAS G12A
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
New immunotherapy option for pancreatic cancer patients with no other choices
Disease control AVAILABLEThis program provides early access to an experimental immunotherapy called ELI-002 7P for people with a specific type of pancreatic cancer (KRAS/NRAS-mutated) who have had their tumor removed but are at high risk of the cancer coming back. It is for patients who have no other tre…
Matched conditions: KRAS G12A
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug targets Hard-to-Treat KRAS cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…
Matched conditions: KRAS G12A
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 20, 2026 11:58 UTC